European Commission approves Adcetris (brentuximab vedotin) for the treatment of adult patients with previously untreated CD30+ stage III Hodgkin Lymphoma in combination with AVD chemotherapy – Takeda
Takeda announced that the European Commission (EC) approved Adcetris (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage… read more.
